INSTITUT CURIE

The VESPER trial (GETUG-AFU V05) compared neoadjuvant and adjuvant chemotherapy in 500 patients with bladder cancer. Neoadjuvant dose-dense MVAC showed better 3-year progression-free survival (66% vs. 56%) and overall survival (HR 0.71) compared to gemcitabine and cisplatin. The BaSq subtype was associated with worse outcomes regardless of chemotherapy type. Key questions remain regarding biological bases of mixed tumors, clinical heterogeneity detection, and improving BaSq tumor prognosis.

Nicolas Girard discusses Teliso-V's promising efficacy and manageable safety profile in c-Met–overexpressing, EGFR wild-type, nonsquamous NSCLC, with improved QOL and cancer-related symptoms like cough and chest pain, as reported in the LUMINOSITY trial. Patient-reported outcomes (PROs) show Teliso-V's benefits align with clinical data, though peripheral neuropathy requires monitoring.